HK Stock Market Move | INNOGEN-B(02591) surges by over 5%; officially enters the Hang Seng Index next Monday. Institutions claim it meets the inclusion criteria for the Hong Kong Stock Connect.

INNOGEN-B (02591) rose by more than 5%, with its stock price currently showing three consecutive gains. As of the time of writing, it has increased by 5.03% to 43.42 Hong Kong dollars, with a trading volume of 7.6433 million Hong Kong dollars. On the news front, the results of the quarterly review of the Hang Seng Index series were previously announced, and SilverNova Medicine was included in the Hang Seng Composite Index as a constituent stock, with the changes taking effect from December 8, 2025. According to Zhongjin's forecast, SilverNova Medicine and others will meet the criteria for inclusion in the Hong Kong Stock Connect. Public information shows that SilverNova Medicine is a biopharmaceutical company focused on metabolic diseases, with a pipeline of innovative drugs for conditions such as diabetes, obesity, and non-alcoholic fatty liver disease, all of which are independently developed and have global intellectual property rights, covering global research and market layout.